Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills(Cancer Research UK Clinical Trials Unit), Alan K. Burnett(Cardiff University), Megan Othus(Cancer Research And Biostatistics), Anthony V. Moorman(Newcastle University), Norbert Ifrah(Institut National du Cancer), Jean‐Yves Cahn, Sylvie Chevret(Saint Louis University Hospital), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Elihu H. Estey(University of Washington), Lucy Chilton(Newcastle University), Jacques Delaunay(Hôtel-Dieu de Paris), Sylvie Castaigné(Hôpital André Mignot), Hervé Dombret(University of London Institute in Paris), Stephen H. Petersdorf(Fred Hutch Cancer Center), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 703
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k